Create your beautiful and unique blog. It's Free.

Latest Blogs




Currently, several companies claim to be engaged in the development / manufacturing of various types of autoinjectors, most of which are disposable systems that use prefilled syringes as primary drug containers, claims Roots Analysis

In addition to enabling patients to self-medicate, these devices are designed to ensure safety during the dosing process and promote compliance to prescribed therapeutic regimens. Moreover, the adoption of autoinjectors, and other self-injection products, has enabled significant cost savings for end users by eliminating the need to visit hospitals / out-patient clinics for dosing.   To order this 600+ page report, which features 360+ figures and 350+ tables, please visit this link   The USD 2.5 billion (by 2030) financial opportunity within the global autoinjectors market has been analyzed across the following segments: Usability Disposable Reusable Route of administration Subcutaneous Intramuscular Type of molecule Antibody Peptide Protein Small molecule Therapeutic indication Anaphylaxis Diabetes Migraine Multiple sclerosis Rheumatoid arthritis Other indications Key geographical regions North America Europe Asia-Pacific Rest of the World   The Global Autoinjectors Market (3rd Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain: Antares Pharma Consort Medic

Details

The global autoinjectors market is projected to grow at an annualized rate of ~10% and be worth around USD 2.5 Billion, till 2030

Roots Analysis has done a detailed study on Global Autoinjectors Market (3rd Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   To order this 600+ page report, which features 360+ figures and 350+ tables, please visit this link   Key Market Insights Currently, several companies claim to be engaged in the development / manufacturing of various types of autoinjectors, most of which are disposable systems that use prefilled syringes as primary drug containers About 90 autoinjector-based combination products have been approved for the treatment of a variety of clinical conditions; the subcutaneous route being the preferred mode of drug delivery via such devices In order to gain a competitive edge in the market, many autoinjector manufacturers are focusing on the integration of advanced features into their respective products and affiliated offerings Over time, more than 4,600 patents have been filed / granted related to autoinjectors and affiliated products; most of the new intellectual

Details

The global autoinjectors market is projected to grow at an annualized rate of over 10%, till 2030

Autoinjectors have become an important part of modern healthcare, having demonstrated the potential to address a number of parenteral drug delivery related adverse events, and improve medication adherence among patients   Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Autoinjectors Market (3rd Edition), 2020-2030.”   The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of autoinjectors over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes: A detailed assessment of the current market landscape of developers engaged in the development and / or manufacturing autoinjectors.  A detailed assessment of current landscape of companies that are developing drugs in combination with autoinjectors. A competitiveness analysis of various disposable and reusable autoinjectors. A detailed brand positioning analysis

Details

The “Antibody Discovery: Services and Platforms Market (3rd Edition), 2020-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely future evolution in this industry over the next ten years

To order this 450+ page report, please visit this link   Key Inclusions An overview of the overall landscape of antibody discovery service providers along with the information on a number of parameters, such as year of establishment, company size, location of headquarters, type of service offered (antigen designing, hit generation, lead selection, and lead optimization and lead characterization), type of antibody discovery method (hybridoma based, library based, single cell based, transgenic animal based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others), type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others) and purpose of antibody discovery (therapeutic and diagnostic). An insightful competitiveness analysis of antibody discovery service providers, based on supplier strength (based on a company's employee count and years of experience) and service portfolio specifications, such as number of antibody discovery services offered, number

Details

Over 80 firms are involved in providing antibody drug discovery-related services; whereas close to 125 players are offering antibody discovery platforms

According to experts in this field, the industry is investigating antibodies against novel targets which are expected to drive the market in the coming years. In fact, many service provider and platform provider companies are offering support to the medical research community in order to develop an appropriate intervention to treat the illness caused by the SARS-CoV-2 virus.   To order this 500+ page report, which features 120+ figures and 140+ tables, please visit this link   The USD 6.5 billion (by 2030) financial opportunity within the antibody discovery services market has been analyzed across the following segments: Steps Involved in the Antibody Discovery Process Antigen Designing Hit Generation Lead Selection Lead Optimization Lead Characterization   Antibody Discovery Method Used Phage Display Hybridoma Transgenic Animal Yeast Display Single Cell Others   Nature of Antibody Generated Humanized Human Chimeric Murine   Key Geographical Regions  North America Europe Asia Pacific and Rest of the

Details

The antibody discovery services and platforms market is projected to grow at an annualized rate of ~10%, till 2030

Roots Analysis has done a detailed study on Antibody Discovery: Services and Platforms Market (3rd Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   To order this 450+ page report, which features 120+ figures and 140+ tables, please visit this link   Key Market Insights Over 80 companies are offering antibody discovery services; of these, more than 75 players claim to offer services related to hit generation. Nearly 180 innovative technology platforms have been developed by numerous firms for the purpose of antibody discovery. Majority of stakeholders in the competitive market landscape are small / mid-sized firms, catering to the needs of a diverse clientele. In order to get an edge over their competitors in the industry, companies have established their presence in different regions across the globe. The rising interest in this field is reflected in the number of partnerships inked in the recent past, involving both international and indigenous stakeholders, and focused on antibody

Details

The antibody discovery services market is estimated to be worth around USD 6.5 billion by 2030 instead the antibody discovery platforms market is anticipated to be worth close to USD 6 billion by 2030, predicts Roots Analysis

Antibody therapeutics have made it possible to address the hard to target hotspots, rendering the domain of antibody discovery an emerging sector in the pharmaceutical industry; in fact, the antibodies have proven to be promising weapons in the battle against COVID-19 pandemic.   Roots Analysis is pleased to announce the publication of its recent study, titled, “Antibody Discovery: Services and Platforms Market (3rd Edition), 2020-2030.”   The report features an extensive study of the current market landscape, offering an informed opinion on the likely evolution in this industry over the next ten years. It features an in-depth analysis of the antibody discovery technologies and services that assist in the development of antibody therapeutics. In addition to other elements, the study includes: A detailed overview of the overall landscape of antibody discovery service providers along with the information on a number of relevant parameters. An insightful competitiveness analysis of antibody discovery service providers based on various relevant parameters, such

Details

Growing at an annualized rate of over 9%, the antibody discovery services market is projected to be worth USD 6.5 billion by 2030; the antibody discovery platforms market is estimated to be worth close to USD 6 billion by 2030: Roots Analysis

  High target specificity and favorable safety profiles offered by antibody based pharmacological interventions has created a high demand for such molecules; the domain has witnessed an increased inflow of investments and collaboration opportunities.   London   Roots Analysis has announced the addition of “Antibody Discovery: Services and Platforms Market (3rd Edition), 2020-2030” report to its list of offerings.   The development of such biologics is inherently complex, and many drug developers are now seeking to optimize R&D efficiency and affiliated costs. As a result, innovator companies are outsourcing most of their discovery-stage operations to specialty contract research organizations (CROs), which offer a plethora of advanced technologies to cater to the evolving needs. It is also worth highlighting that stakeholders engaged in this domain are actively undertaking initiatives to develop interventions for SARS-CoV-2 virus.   To order this 450+ page report, which features 120+ figures and 140+ tables, please visit this link   Key Market Insights    Presently, more than 80 players claim to offer ser

Details

The ‘‘Microbial Contract Biomanufacturing Market, 2020-2030’’ report

To order this detailed 320+ page report, please visit this link   Key Inclusions A detailed review of the current landscape of companies offering contract manufacturing services for biologics, using microbial expression systems, along with information on their year of establishment, company size, location of headquarters, number and location of their production facilities, scale of operation (preclinical, clinical and commercial), type of biologic(s) manufactured (peptides / proteins, antibodies, vaccines, biosimilars, oligonucleotides, plasmid DNA and others), type of microbial expression system(s) used (bacterial, yeast and others), type of fermenter(s) employed (single-use fermenters, stainless steel fermenters and others), type of manufacturing service(s) offered (cell banking, process development and characterization, analytical method development and testing, quality assurance and control, scale-up, downstream processing and regulatory support), and regulatory accreditations / certifications received (if any). A region-wise, company competitiveness analysis, highlighting

Details

The ‘‘Microbial Contract Biomanufacturing Market, 2020-2030’’ report

Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly. Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics. Given the obvious advantages of outsourcing, drug developers are likely to continue relying on contract service providers for various aspects of their respective microbial biologic development programs.   To order this 320+ page report, which features 150+ figures and 150+ tables, please visit this link   The USD 9.3 billion (by 2030) financial opportunity within the microbial biomanufacturing market has been analyzed across the following segments: Type of Product API FDF   Type of Biologic Proteins Enzymes Growth Hormones Antibody based Drugs Others (plasmid DNA, probiotics, microbiome-based biologics)   Type of Microbial Expression System Bacteria Yeast Others

Details

The microbial contract biomanufacturing market is projected grow at an annualized rate of 8.7%, till 2030

Roots Analysis has done a detailed study on Microbial Contract Biomanufacturing Market, 2020-2030, covering key aspects of the industry and identifying potential future growth opportunities.   To order this 320+ page report, which features 150+ figures and 150+ tables, please visit this link   Key Market Insights Over 115 companies, across the world, claim to offer a variety of product development, manufacturing and support services, for various types of biologics that are manufactured / expressed in microbial systems Majority of the players have the necessary infrastructure / capability to produce different biologics, primarily proteins, at all scales using bacterial / yeast expression vectors The market features the presence of several well-established players across the globe; the US, the UK and Germany emerged as current hubs for production of biologics using microbial strains Several service providers, involved in this domain, are steadily expanding their capabilities in order to enhance their respective service portfolio and maintain a competitive edge in the

Details

The microbial contract biomanufacturing market is estimated to be worth USD 9.3 billion in 2030, predicts Roots Analysis

Benefits offered by microbial biomanufacturing, such as low production costs and faster development timelines, have led many innovators to adopt these platforms for next generation biologics, offering lucrative opportunities for CMOs / CDMOs   Roots Analysis is pleased to announce the publication of its recent study, titled, “Microbial Contract Biomanufacturing Market, 2020-2030.”   The report features an extensive study of the current market landscape and future opportunities associated with the microbial contract biomanufacturing market. It features a detailed analysis of key drivers and trends related to this evolving domain. In addition to other elements, the study includes: A detailed review of the current landscape of companies offering contract manufacturing services. Elaborate profiles of key players that specialize in offering services for contract biomanufacturing. A competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing, featuring insightful pictorial summaries and representations. An analysis of

Details

The microbial contract biomanufacturing market is projected to be worth USD 9.3 billion by 2030, growing at a CAGR of 8.7%, claims Roots Analysis

The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated to offer lucrative opportunities to service providers serving this niche, but growing market segment     London   Roots Analysis has announced the addition of the “Microbial Contract Biomanufacturing Market, 2020-2030” report to its list of offerings.   Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly. Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics. Given the obvious advantages of outsourcing, drug developers are likely to continue relying on contract service providers for various aspects of their respective microbial biologic development programs.   To order this 320+ page report, which

Details

The “STING Pathway Targeting Therapeutics and Technologies, 2020-2030”

To order this detailed 310+ page report, please visit this link     Key Inclusions   A detailed assessment of the current market landscape of therapeutics targeting STING pathway, based on several parameters, such as type of STING modulator (agonist or antagonist), type of molecule (small molecules, cyclic dinucleotides, non-nucleotides, biologics and others), phase of development (discovery, preclinical and clinical), target therapeutic area(s), type of therapy (monotherapy and combination therapy), route of administration (intratumoral, intravenous and others), and line of treatment (last line, second line or greater and first line or greater). The chapter also features an analysis of the developer landscape (including information on year of establishment, company size, geography and most active players). Further the chapter includes an analysis on the clinical trials focused on STING, along with information on parameters, such as recruitment status, study design and clinical endpoints. A detailed chapter highlighting various technology platforms that are being

Details

Many small / macro molecule-based STING pathway modulators are currently being evaluated as monotherapies as well as in combination with other drugs, claims Roots Analysis

In recent years, the concept of STING pathway targeting therapeutics has generated a lot of enthusiasm within the medical science community. The growing popularity of this therapeutic technique has not only garnered the interest of several medical researchers (reflected in the increasing volume of scientific literature (1,000+ articles published since 2015) on this subject), but also industry stakeholders focused on drug development (evident in the growing number of clinical trials and the grants awarded for STING focused projects in the recent past).   To order this 310+ page report, which features 170+ figures and 200+ tables, please visit this link   The USD 2.8 billion (by 2030) financial opportunity within the STING pathway targeting technologies market has been analysed across the following segments: Types of Payment Upfront Payments Milestone Payments   Type of STING Modulator Agonist Antagonist   Key Therapeutic Area(s) Oncological Disorders Inflammatory Disorders Infectious Diseases Others   Route of Administration Intratumoral Intravenous Oral Subcutaneous Others   Type

Details

The STING pathway targeting technologies market is projected to grow at an annualized rate of ~25%, till 2030

Roots Analysis has done a detailed study on STING Pathway targeting therapeutics and Technologies, 2020-2030, covering key aspects of the industry and identifying future growth opportunities.   To order this 310+ page report, which features 150+ figures and 200+ tables, please visit this link   Key Market Insights Many small / macro molecule-based STING pathway modulators are currently being evaluated as monotherapies as well as in combination with other drugs The pipeline features candidates targeting different therapeutic areas and designed for administration through a variety of routes; majority of such therapeutics are being developed as third-line and second-line treatments In recent years, several well funded start-ups have entered this field of research, and are gradually developing proprietary products based on the STING pathway for the treatment of a variety of indications In addition, a number of big pharmaceutical players have also partnered with developers focused on STING targeting molecules in order to expand their respective capabilities in this upcoming

Details

The STING pathway targeting technologies market, featuring a healthy pipeline of therapeutics, is anticipated to be worth over USD 2.8 billion by 2030, predicts Roots Analysis

STING, having generated significant interest within the medical research community, is currently considered one of the fastest growing areas of cancer immunotherapy and is being pursued by several large pharmaceutical companies   Roots Analysis is pleased to announce the publication of its recent study, titled, “STING Pathway Targeting Therapeutics and Technologies, 2020-2030.”   The report features an extensive study of the current market landscape and future potential of these therapeutics and affiliated technologies, over the next decade. This study focuses specifically on small molecule STING modulators. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes: A detailed assessment of the current market landscape of therapeutics targeting STING Pathway.  A detailed assessment of the current market landscape of various technology platforms that are being actively used for the development of STING modulators. Detailed profiles of

Details

United Airlines Flight Cancellation

United Airlines Flight Cancellation policy is designed to offer its passengers the best of experiences.  Our 24 hours cancellation policy is the same for all categories. We offer a 24 hours window before charging you for the cancellation.If you want to skip the process and get someone else to do it on your behalf, just reach out to our customer support executives at +1 (877) 232-4253 (Contact number). All you need to do it is to ask them. They are well trained and will get your flight canceled in no minutes.

Details

United Airlines Flight Cancellation

United Airlines Flight Cancellation policy is designed to offer its passengers the best of experiences.  Our 24 hours cancellation policy is the same for all categories. We offer a 24 hours window before charging you for the cancellation.If you want to skip the process and get someone else to do it on your behalf, just reach out to our customer support executives at +1 (877) 232-4253 (Contact number). All you need to do it is to ask them. They are well trained and will get your flight canceled in no minutes.

Details

United Airlines Flight Cancellation

United Airlines Flight Cancellation policy is designed to offer its passengers the best of experiences.  Our 24 hours cancellation policy is the same for all categories. We offer a 24 hours window before charging you for the cancellation.If you want to skip the process and get someone else to do it on your behalf, just reach out to our customer support executives at +1 (877) 232-4253 (Contact number). All you need to do it is to ask them. They are well trained and will get your flight canceled in no minutes.

Details
Page 4 of 245
FREE BLOG/SBM SITES
Categories